Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

HCM - Hypertrophic Non-Obstructive Cardiomyopathy Clinical Trial

Official title:

A Pilot Study Assessing the Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03953989
• Other study ID #: HCMRanIT001
• Status: Completed
• Phase: Phase 2
• Start date: October 2016
• Est. completion date: March 6, 2020

Study information

• Verified date: December 2020
• Source: IRCCS San Raffaele
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To demonstrate the efficacy of ranolazine in improving coronary microvascular and diastolic dysfunction in patients affected by HCM evaluating changes in maximum (i.e. during dipyridamole-induced coronary vasodilatation) myocardial blood flow (MBF) measured by PET at baseline and after 4 months of treatment with ranolazine in patients with non obstructive HCM.

Description:

This pilot study aimed at assessing the effects of treatment with ranolazine, on top of optimal standard medical therapy (according to international guidelines), on microvascular dysfunction using PET in patients with HCM.

Thirty months of enrolment are foreseen. Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment. Visit 0,1,2,3 may be performed 3 days before or 3 days after the planned date. Visit 4 and final PET scan may be performed 15 days before or 15 days after the planned date.

This is a superiority study. The sample size calculation is based on the ANOVA model, but the statistical analysis will be performed applying the ANCOVA model for the absence of data on the correlation between basal and end of study values of the primary variable studied. As previously reported (Camici et al. J Am Coll Cardiol 1991; 17:879-86) maximum (i.e. during dipyridamole stress) MBF is severely blunted in HCM (1.63±0.58 mL/min/g) compared to control subjects (2.99±1.06 mL/min/g). For the primary end-point of the study using a two-sided test at 5% significance level, with a power of 90% and a SD of ± 0.7 mL/min/gr, in order to detect a change of 0.5 mL/min/gr in maximum MBF before and after treatment, 24 patients valid per protocol are required.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: March 6, 2020
• Est. primary completion date: February 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Male and female gender (females of childbearing potential must be using highly effective contraceptive precautions such as implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence or vasectomised partner);

• Females of childbearing potential or within two years from the menopause must have a negative urine pregnancy test;

• Patients which fulfill conventional echocardiographic criteria for the diagnosis of HCM: maximum LV wall thickness = 15 mm;

• Patients aged > 18 years and < 80 years;

• Sinus rhythm accepted isolated Supraventricular and Ventricular Premature Beats (VPB);

• Absence of severe resting LV outflow tract obstruction (peak gradient = 50 mmHg);

• Written informed consent prior to enrolment into the study;

Exclusion Criteria:

• Females of childbearing potential not using highly effective contraceptive precautions;

• Presence of known coronary artery disease (CAD);

• Presence of Chronic Obstructive Airways Disease;

• Asthma;

• Other causes of microvascular dysfunction including long-standing history of arterial hypertension, diabetes, uncontrolled dyslipidemia;

• Body mass index >32 kg/m2; < 17 kg/m2

• Overt LV systolic dysfunction with end-stage progression (LV-EF <50%);

• Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazol, posaconazol, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone);

• Patients treated with sotalol, dronedarone, class I antiarrhythmics (see appendix 4) or other QT-prolonging drugs; stable treatment with amiodarone is permitted;

• Patients with QTc (Bazett's formula) at baseline = 450 ms males; =470 msec females;

• Any clinically relevant haematological or biochemical abnormality on routine screening, according to Investigator's judgment;

• Severe concurrent pathology, including terminal illness (cancer, AIDS, etc.);

• Severe renal impairment defined as GFR < 29 mL/min/1.73m2 or creatinine level > 2.5 mg/dL or BUN >60 mg/dL;

• Moderate or severe hepatic impairment or hepatic insufficiency defined as SGOT or SGPT > 2 times greater than normal upper limit of the local laboratory or total serum bilirubin > 1.5 times greater than normal upper limit of the local laboratory;

• Dementia, psychosis, alcoholism (>350 g ethanol/week) or chronic abuse of medicaments, drugs or psychoactive substances;

• Claustrophobia;

• Females who are pregnant or lactating;

• Conditions that in the Investigator's opinion may interfere with the study's execution or due to which the patient should not participate for safety reasons;

• Risk of poor patient cooperation;

• Participation in a clinical study = 2 months before enrolment;

• Inability or unwillingness to issue the informed consent;

• Concomitant use of > 20 mg daily dose of Simvastatin during the study (in case of patients taking simvastatin > 20 mg daily, the switch to other statins not metabolized by the CYP3A4 could be considered);

• Concomitant use of Atorvastatin (> 80 mg daily)

• Concomitant use of > 1000 mg daily dose of metformin during the study

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Hypertrophic
• HCM - Hypertrophic Non-Obstructive Cardiomyopathy
• Hypertrophy

Intervention

Drug:
• Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die
Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment

Locations

Country	Name	City	State
Italy	IRCCS Ospedale San Raffaele	Milan

Sponsors (2)

Lead Sponsor	Collaborator
IRCCS San Raffaele	Menarini International Operations Luxembourg SA

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Myocardial Blood Flow during hyperemia ml/min/g	Change of near maximal hyperemic myocardial blood flow (MBF ml/min/g) after treatment with ranolazine of at least 0.5 ml/min/g. Myocardial perfusion measured with 13N-ammonia and positron emission tomography at rest and during hyperemia; Hyperaemic Myocardial Blood Flow (MBF) measured following i.v. dipyridamole (0.56 mg/Kg in 4 mins)	At baseline and after 4 months of treatment
Primary	Coronary Flow Reserve (hyperaemic MBF /resting MBF = CFR).	Change of CFR after treatment with ranolazine for four months	At baseline and after 4 months of treatment
Primary	Coronary resistance	Change of Resting coronary resistance (Mean Arterial Pressure rest/ MBF rest) and minimal (during hyperemia) coronary resistance (Mean arterial Pressure hyperemia/ MBF hyperemia)	At baseline and after 4 months of treatment
Secondary	Symptoms	Number of participants with absence of symptoms accountable for drug intolerability ,assessed through customized questionnaire. If symptoms are accountable for drug intolerability are referred, the patient will come back to 500 mg/bid.	through 4 month of treatment